I never thought we'd be at $0.03 either. Rs from this level for uplist would be a disaster for shareholders AND the company, which is why the rs does not need to be implemented at all, and is not effective immediately. So I continue to believe that there is more planned, and that the insider shares, including those most recently issued to directors, will have increased value.
Shareholder wishlist is being implemented:
Armen eliminating the preferred shares.
Armen eliminated his consulting fee.
Armen eliminated the compounding pharmacist consulting fee.
The fee changes AND expanded services resulted in a nice Q3 profit.
If rs is implemented, Authorized Shares will be reduced to 100M.
If rs is implemented, it will be for uplist to NASDAQ, "on or before February 16, 2023" (14 months to implement!)
RXMD is doing things that the shareholders have asked for, but still paying for past debt with shares, the dilution will end, but it is killing shareholder value! I blame Mars as much as Armen!
IMO, the only thing RXMD is failing to deliver is Shareholder ROI. I hoped for that by now, but I believe they are working on organic growth and they just set a 14 month deadline to make it happen. It's not like the rs is imminent. There is a plan, IMO. A lot can happen in 14 months, especially with their technology products. It's unfortunate that 14 months is about 24 months past when I expected my ROI. I so wish I just found RXMD and loaded at this level. #LuckyNewbies
I'm certainly not selling at this level. I added 40K last week at $0.0303.
Go RXMD!
News 
Market Data 
Discover 
AI
